Contribute Try STAT+ Today

Bluebird Bio said Tuesday that it has suspended clinical trials involving its gene therapy for sickle cell disease after receiving reports that two patients treated with the one-time therapy were diagnosed with cancer.

The trials were placed on “temporary suspension” so that Bluebird can investigate the cancer cases to determine if they were caused by the re-engineered HIV virus used to deliver its gene therapy. No such link has been established yet, the company said.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • You stated this:
    “The investigation of the cancer cases will seek to determine if the Lentiglobin gene therapy could have caused the patients’ cancer, by possibly inserting the modified stem cells in the wrong place. This is a theoretical risk for any gene therapy that uses viruses as a delivery vehicle, but had not yet materialized in clinical trials until Bluebird’s reports.” There are several problems with this comment. One is that it is the modified GENE that is inserted in the wrong place in the blood stem cells. Additionally, the advent of leukemia in a gene transfer clinical trial in which hematopoietic (blood) stem cells are modified, is not a new phenomenon. There were several cases of leukemia in the early gene transfer clinical trials for X-linked Severe Combined Immunodeficiency Disease (X-SCID); the viral vector used for those trials was a retroviral vector. See: Hacein-Bey-Abina S, Garrigue A, Wang GP, et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest. 2008;118(9):3132-3142. doi:10.1172/JCI35700

  • I am very upset for this news.
    Just now that Gene Therapy was so close to the clinical practice.
    But I am confident .

Comments are closed.